Fig. 10
Synergism achieved by combining myricetin with ARVs for inhibition of infection by HIV-1SF162 in semen. Compounds were examined at fixed molar ratios individually and in combination. a Myr and MAR (2095:1); b Myr and AZT (1571:1); c Myr and TNF (62.8:1); d Myr and EFV (3142:1); e Myr and NVP (628:1); f Myr and RAL (3142:1). Luciferase activities were measured at 72 h post-infection. Each sample was tested in triplicate, and the data are presented as the mean ± SD